An experimental electric comb developed at Beihang University in Beijing regrew nearly 98% of hair in mice with male-pattern baldness in 28 days, outperforming minoxidil, the most widely used hair-loss drug. The device, called Detangle, has not yet been tested in humans.
The study, published on November 3 in Nature Communications, targets androgenetic alopecia — the most common form of progressive hair loss, which the researchers say affects more than 1.5 billion people worldwide. DW reported the findings this week, and several outlets have since picked them up with strikingly different framings.
Here is the gap between expectation and result. Mice that received no treatment regrew almost none of their shaved fur — about 1%. The full Detangle system, combining electrical stimulation with two experimental molecules, restored 97.85% of hair coverage in the treated area within a month, according to Science Alert’s summary of the study, which DW cited.
Comb works in mice, not yet in humans
- The comb works in mice, not people. No human trial has taken place yet, so no one can buy or use it as a treatment today.
- It combines two ideas: gentle electric pulses that push therapeutic molecules deeper into skin, and those molecules themselves — one that grows blood vessels around follicles, one that lowers DHT, the hormone that shrinks follicles in pattern baldness.
- Existing drugs still work for many people, but imperfectly — and none of them is a cure.
How Detangle reaches the follicle
The device looks like an ordinary comb, but its teeth differ in height and carry electrodes plus small reservoirs of therapeutic substances. When drawn across skin, the teeth lift it slightly and deliver electrical impulses that help molecules penetrate deeper layers and stimulate the hair follicles directly.

The arrangement matters. Science Alert, cited by DW, reported that the staggered teeth generate an electric field 2.63 times more intense than aligned teeth would, and that the field reaches roughly nine times deeper in the follicle zone than conventional external application. El Nacional, in its own report, put the delivery depth at about 0.66 millimeters.
The two payloads do different jobs. One is a plasmid — a small ring of DNA carrying instructions to produce VEGFA, a protein that promotes blood vessel formation around follicles, improving their supply of oxygen and nutrients.
The other is a small interfering RNA, or siRNA, targeting SRD5A2, the gene for the enzyme 5-alpha-reductase type 2, which produces dihydrotestosterone (DHT). In androgenetic alopecia, follicles are hypersensitive to DHT, which progressively miniaturizes them until they produce only fine, short hairs.
What the mouse numbers actually show
Researchers shaved the backs of male mice and applied daily testosterone to induce a condition mimicking androgenetic alopecia, then compared treatments over 28 days. The results, as compiled across DW’s and La Razón’s reports, form a clear ladder:

| Treatment (28 days) | Hair regrowth in treated area |
|---|---|
| No treatment | ~1% |
| Electric stimulation alone (no molecules) | ~40% |
| Finasteride | ~50% |
| Minoxidil | ~70% |
| Full Detangle system | 97.85% |
Tissue examination showed more active follicles and better local blood circulation in the treated zone, New Atlas reported, and Eldiario’s account added that the team observed reduced DHT and lower markers of inflammation. Gizmodo en Español reported that safety checks found no observable damage to the mice’s skin.
The contrast between the electrical stimulation alone (40%) and the full system (97.85%) is the study’s central finding: the electric field is a delivery mechanism, not the therapy itself.
Why current treatments fall short
The limitations the researchers are trying to overcome are real and well documented. DW reported that only a small fraction of topically applied minoxidil penetrates the skin barrier to reach the follicles. Oral minoxidil can cause unwanted hair growth elsewhere; topical formulas are messy and, for some users, irritating.
Results also vary person to person. The Independent said that minoxidil can take up to a year to show effects and must be continued to maintain them. Finasteride, taken orally, can cause side effects including erectile dysfunction and depression. Hair transplantation works but is invasive and costly.
The scale of the problem is large. The Independent reported that male-pattern baldness affects up to 80% of men over their lifetimes, and can carry psychological consequences — yet treatment options remain limited.
From mouse bench to human scalp
Every outlet that covered this study carried the same caveat, and it is the most important one: Detangle has not been tested in humans. Mouse results can suggest whether a treatment is worth pursuing, but they do not demonstrate that the same effect, safety profile, or dosing will hold on a human scalp, which differs in thickness, follicle density, and drug penetration.
Regulatory paths will also differ by region. In the United States, a device-plus-drug combination like this would face review by the FDA as a combination product; in Europe, it would fall under EMA and medical-device frameworks; in the UK, the MHRA would assess it. None of these pathways has been initiated, as no clinical trial has been announced.

The study itself, by Liu et al. and titled “Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia,” is published open access in Nature Communications.
One distinction matters for readers: this is not related to alopecia areata, an autoimmune condition with a different mechanism. La Razón flagged the confusion explicitly, noting that recent advances in areata treatment should not be conflated with this androgenetic alopecia work.
Consult a dermatologist for current treatment options
Because Detangle is not available to the public, there is nothing to self-administer — and any consumer product claiming similar electric-comb hair regrowth should be treated with skepticism. People experiencing hair loss who want treatment today should consult a dermatologist, who can diagnose the type of alopecia, since androgenetic alopecia, alopecia areata, and telogen effluvium require different approaches.
Anyone using finasteride who experiences sexual side effects or mood changes, or using minoxidil without results after a sustained period, should discuss alternatives with their physician rather than adjusting doses on their own.
The knot still to untangle
The researchers themselves, per DW’s account, frame the results as promising but preliminary: safety, efficacy, duration of effects, and the implications of repeated use all remain to be established in humans. Gizmodo en Español noted the team’s suggestion that the delivery system could eventually have broader dermatological applications beyond hair.
The strongest fact in the story is also the one that should temper excitement: 97.85% regrowth was measured on the shaved backs of mice over 28 days. Before Detangle becomes a treatment, as DW put it, it faces a knot considerably harder to untangle than any in hair.
Beihang University, where the comb was developed, was founded in 1952 as Beijing Aeronautics College, formed by merging the aerospace engineering departments of eight universities, including Tsinghua University and Xiamen University.
It was the first aerospace higher education institution in New China and was renamed Beijing University of Aeronautics and Astronautics in April 1988. Today it counts more than 40 research achievements that were the first in China and has won top national science and technology awards more than 70 times.
References
- Liu et al., “Combing-triggered electrostimulation synchronizing deep delivery for rapid hair regrowth in androgenetic alopecia,” Nature Communications, published November 3, 2026. nature.com/articles/s41467-026-79122-3
- DW — reporting on the Detangle study and treatment limitations.
- La Razón — comparative trial figures and the alopecia areata distinction.
- Eldiario (Quo) — siRNA mechanism detail, mouse protocol, and study reference.
- The Independent en Español — epidemiology of male-pattern baldness.
This article is journalistic coverage of preliminary preclinical research and does not constitute medical advice. Consult a qualified healthcare professional regarding any hair-loss treatment.